| Revue: | Revista de investigación clínica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000453189 |
| ISSN: | 0034-8376 |
| Autores: | Bandala Jacques, Antonio1 Hernández Cruz, Irwin A1 Castro Hernández, Clementina1 Díaz Chávez, José1 Arriaga Canon, Cristian1 Barquet Muñoz, Salim A1 Prada Ortega, Diddier G1 Cantú de León, David1 Herrera, Luis A1 |
| Instituciones: | 1Universidad Nacional Autónoma de México, Instituto de Investigaciones Biomédicas, Ciudad de México. México |
| Año: | 2020 |
| Periodo: | Nov-Dic |
| Volumen: | 72 |
| Número: | 6 |
| Paginación: | 372-379 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Experimental, aplicado |
| Resumen en inglés | Background: Ovarian cancer is the most lethal gynecologic cancer. Although most patients respond adequately to the first-line therapy, up to 85% experience a recurrence of disease, which carries a poor prognosis. Mitotic arrest deficiency 1 is a protein that helps in the assembly of the mitotic spindle assembly checkpoint by preventing anaphase until all chromatids are properly aligned. A single-nucleotide polymorphism in the MAD1L1 gene is prevalent in patients with advanced epithelial ovarian cancer and alters the way in which it responds to chemotherapy. Objective: The objective of the study was to study the relationship between the rs1801368 polymorphism of MAD1L1 and prognosis of ovarian adenocarcinoma. Methods: A total of 118 patients in whom the MAD1L1 gene was sequenced were analyzed using descriptive and comparative statistics. Results: Patients carrying the wild-type genotype had a higher distribution of early-stage disease. Having a MAD1L1 polymorphic allele increased the risk of being non-sensitive to chemotherapy. The median disease-free survival for patients with the wild-type MAD1L1 was 46.93 months, compared to 10.4 months for patients with at least one polymorphic allele. Conclusions: The rs1801368 polymorphism of MAD1L1 gene worsens prognosis in patients with ovarian adenocarcinoma. Traditional therapy for ovarian cancer might not be optimal in patients carrying this polymorphism |
| Disciplinas: | Medicina |
| Palabras clave: | Oncología, Ginecología y obstetricia, Diagnóstico, Adenocarcinoma, Ovarios, Polimorfismo genético, Quimioterapia |
| Keyword: | Gynecology and obstetrics, Oncology, Diagnosis, Adenocarcinoma, Ovaries, Genetic polymorphism, Chemotherapy |
| Texte intégral: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
